Hormonal
Discontinuation of second-generation anti-obesity medications (semaglutide and tirzepatide) leads to rapid and substantial weight regain, often returning to baseline cardiometabolic status, demonstrating the chronic nature of obesity and the need for indefinite treatment.
If you stop taking semaglutide or tirzepatide, you will likely regain most of the weight you lost within a year. This demonstrates that obesity is a chronic condition requiring long-term treatment, similar to high blood pressure. To maintain weight loss, you likely need to continue the medication indefinitely.
Individuals regain weight quickly after discontinuing semaglutide. A subset of 228 STEP-1 participants, who lost a mean 17.3% of baseline weight at week 68, regained an average of two-thirds of their loss (11.6 percentage points) 1 year after discontinuing medication... These results mirror those from STEP 4... confirm the chronicity of obesity and the clear need for its long-term (indefinite) treatment, as with other chronic diseases.
Why this rating
Based on phase 3 trials (STEP 1, STEP 4) with clear follow-up data on weight regain after discontinuation.
Source
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Thomas A. Wadden et al. · Current Obesity Reports · 2023
DOI 10.1007/s13679-023-00534-z
More from this paper
- Second-generation anti-obesity medications (semaglutide 2.4 mg and tirzepatide) induce significantly greater weight loss (15-21%) compared to traditional lifestyle modification (5-10%) by pharmacologically enhancing satiation and reducing hunger, thereby decreasing the reliance on cognitive behavioral strategies for calorie restriction.Strong
- Intensive lifestyle modification (including meal replacements and frequent counseling) combined with semaglutide does not produce significantly greater long-term weight loss than semaglutide alone with brief counseling, suggesting the medication's efficacy may render intensive behavioral interventions redundant for long-term outcomes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →